Kevin Barber

Abstract Genetically encoded voltage indicators have emerged as a tool for resolving neuronal spiking activity with high spatiotemporal resolution within genetically specific populations; however, their fast temporal dynamics, low signal-to-noise ratio (SNR) and fast photobleaching have posed substantial challenges limiting their broader utility and, together with suboptimal optical acquisition schemes, preventing their efficient scale-up to larger neuronal populations.

Newsletter | July 21, 2021 By Ed Miseta, chief editor, Clinical Leader Drug development in the Alzheimer’s space is difficult and has been plagued by successive failures over the last 18 years. One company working in that space felt it was time to take a new and innovative approach to find a treatment for patients.

Newsletter | June 16, 2021 By Ed Miseta, chief editor, Clinical Leader The FDA’s approval of aducanumab for patients with Alzheimer’s disease seems to have surprised some in the industry. There are several take-aways from the decision, and senior industry analysts Marc Engelsgjerd and Sam Fazeli of Bloomberg Intelligence have captured those ideas in a new white paper. By John A. Reaves John A. Reaves was compelled to participate in clinical trials for a COVID-19 vaccine.